LEADER 06711nam 22007575 450 001 9910298642403321 005 20251117075859.0 010 $a3-662-43787-2 024 7 $a10.1007/978-3-662-43787-2 035 $a(CKB)3710000000268435 035 $a(EBL)1968099 035 $a(OCoLC)896848767 035 $a(SSID)ssj0001372314 035 $a(PQKBManifestationID)11734757 035 $a(PQKBTitleCode)TC0001372314 035 $a(PQKBWorkID)11304081 035 $a(PQKB)10251010 035 $a(MiAaPQ)EBC1968099 035 $a(DE-He213)978-3-662-43787-2 035 $a(PPN)182099415 035 $a(EXLCZ)993710000000268435 100 $a20141024d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe Blood Brain Barrier (BBB) /$fedited by Gert Fricker, Melanie Ott, Anne Mahringer 205 $a1st ed. 2014. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2014. 215 $a1 online resource (169 p.) 225 1 $aTopics in Medicinal Chemistry,$x1862-2461 ;$v10 300 $aDescription based upon print version of record. 311 08$a3-662-43786-4 320 $aIncludes bibliographical references and index. 327 $a""Preface""; ""Contents""; ""The Blood-Brain Barrier: An Introduction to Its Structure and Function""; ""1 The BBB: A Historical Perspective""; ""2 Evolutionary Development of a BBB""; ""3 Anatomic Principles of the BBB""; ""4 Pericytes""; ""5 Astrocyte: Endothelium Interactions""; ""6 Neurons""; ""7 Basal Membrane""; ""8 Junctional Complexes at the BBB""; ""9 Transport Proteins at the BBB""; ""10 Cytotic Processes at the BBB""; ""11 Outlook""; ""References""; ""In Vivo Approaches to Assessing the Blood-Brain Barrier""; ""1 Introduction"" 327 $a""2 Pharmacokinetic Principles of Blood-Brain Barrier Transport""""3 Methods""; ""3.1 Brain Uptake Index (Carotid Artery Single Injection Technique)""; ""3.2 The i.v. Injection Technique""; ""3.3 In Situ Brain Perfusion""; ""3.4 Brain Efflux Index""; ""3.5 Percentage of the Injected Dose""; ""3.6 Microdialysis""; ""3.7 CSF Sampling""; ""3.8 Positron Emission Tomography""; ""3.9 Combinatorial Mapping of Kp,uu,brain""; ""4 Conclusions""; ""References""; ""ABC Transporters at the Blood-Brain Barrier""; ""1 Introduction""; ""2 ABC Transporters at the Blood-Brain Barrier"" 327 $a""2.1 Assessing ABC Transporter Activity/Expression""""3 Modulation of ABC Transporter Expression and Activity""; ""3.1 Altered Transporter Expression""; ""3.1.1 Response to Xenobiotics""; ""3.1.2 Response to Disease""; ""3.2 Altered Transporter Activity Through Signaling""; ""3.2.1 Regulation of P-Glycoprotein Activity Through Sphingolipid Signaling""; ""3.2.2 Regulation of P-Glycoprotein Activity Through VEGF Signaling""; ""3.2.3 Regulation of BCRP Activity Through Estrogen Signaling""; ""3.2.4 Mechanisms Underlying Decreased Transporter Activity""; ""4 Perspectives""; ""References"" 327 $a""Nanoparticles as Blood-Brain Barrier Permeable CNS Targeted Drug Delivery Systems""""1 Introduction""; ""1.1 Blood-Brain Barrier""; ""1.2 Blood-Cerebrospinal Fluid Barrier (BCB) and CSF-Brain Barrier""; ""1.3 CNS Drug Delivery Strategies""; ""1.4 Nanomedicine Exploitation""; ""1.5 Nanomedicines for BBB Crossing: General Considerations""; ""2 BBB Crossing Nanocarriers""; ""2.1 Poly(n-butylcyanoacrylate) (PBCA) NPs""; ""2.2 Methoxypoly(ethylene glycol)-polylactide or Poly(lactide-co-glycolide) (mPEG-PLA/PLGA) NPs""; ""2.3 Liposomes""; ""2.4 Inorganic Nanosystems""; ""3 Conclusions"" 327 $a""References""""Blood-Brain Barrier and Stroke""; ""1 Introduction""; ""2 Injury to BBB Cell Components After Stroke""; ""2.1 Endothelial Cells""; ""2.2 Pericytes""; ""2.3 Astrocytes""; ""3 Basement Membrane, Extracellular Matrix, and Stroke""; ""4 Systemic and Local Inflammation and BBB Permeability After Stroke""; ""4.1 Chemokines, Adhesion Molecules, and Leukocyte Trafficking""; ""4.2 Parenchymal Brain Cells""; ""4.3 Perivascular Inflammatory Cells""; ""5 Post-ischemic Vascular and Brain Repair""; ""6 BBB Responses to Stroke in the Perinatal Period"" 327 $a""7 BBB Integrity, Angiogenesis, and Brain Repair After Stroke During the Perinatal Period"" 330 $aMedicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors. 410 0$aTopics in Medicinal Chemistry,$x1862-2461 ;$v10 606 $aPharmaceutical chemistry 606 $aMolecular biology 606 $aPharmacology 606 $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 615 0$aPharmaceutical chemistry. 615 0$aMolecular biology. 615 0$aPharmacology. 615 14$aMedicinal Chemistry. 615 24$aMolecular Medicine. 615 24$aPharmacology/Toxicology. 676 $a54 676 $a611.01816 676 $a615 676 $a615.19 702 $aFricker$b Gert$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aOtt$b Melanie$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aMahringer$b Anne$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910298642403321 996 $aBlood Brain Barrier (BBB)$93365369 997 $aUNINA